These data suggested reduction in chromatin accessibility in the promoter and enhancer regions of the FOXA2 locus in the never-met tumor relative to the metastatic-associated tumor after normalization (Peaknorm log2FC = 2.47, Padj = 0.075) (Fig. 6c). This evidence concerns the gene FOXA2 and neoplasm.